<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20241031//EN" "JATS-journalpublishing1-4.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.4" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">oju</journal-id>
      <journal-title-group>
        <journal-title>Open Journal of Urology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2160-5629</issn>
      <issn pub-type="ppub">2160-5440</issn>
      <publisher>
        <publisher-name>Scientific Research Publishing</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.4236/oju.2026.1611055</article-id>
      <article-id pub-id-type="publisher-id">oju-155390</article-id>
      <article-categories>
        <subj-group>
          <subject>Article</subject>
        </subj-group>
        <subj-group>
          <subject>Medicine</subject>
          <subject>Healthcare</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Bladder Metastasis from Gastric Signet-Ring Cell Adenocarcinoma: A Report of Two Cases</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dieng</surname>
            <given-names>Djiby</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jemaa</surname>
            <given-names>Mohamed Ben</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Benaida</surname>
            <given-names>Abdelghani</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Oponguy</surname>
            <given-names>Christ Albertin Obongha Ondzé</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nkurunziza</surname>
            <given-names>Steve</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Eddine</surname>
            <given-names>Omar Zine</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mezepo</surname>
            <given-names>Garvey</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Glabeke</surname>
            <given-names>Emmanuel Van</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label> Department of Urology, André Grégoire Intercommunal Hospital Center of Montreuil, Montreuil, France </aff>
      <author-notes>
        <fn fn-type="conflict" id="fn-conflict">
          <p>The authors declare no conflicts of interest.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>11</day>
        <month>11</month>
        <year>2026</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>11</month>
        <year>2026</year>
      </pub-date>
      <volume>16</volume>
      <issue>11</issue>
      <fpage>545</fpage>
      <lpage>553</lpage>
      <history>
        <date date-type="received">
          <day>28</day>
          <month>07</month>
          <year>2026</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>11</month>
          <year>2026</year>
        </date>
        <date date-type="published">
          <day>18</day>
          <month>11</month>
          <year>2026</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2026 by the authors and Scientific Research Publishing Inc.</copyright-statement>
        <copyright-year>2026</copyright-year>
        <license license-type="open-access">
          <license-p> This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link> ). </license-p>
        </license>
      </permissions>
      <self-uri content-type="doi" xlink:href="https://doi.org/10.4236/oju.2026.1611055">https://doi.org/10.4236/oju.2026.1611055</self-uri>
      <abstract>
        <p>Although primary bladder cancer is the second most common urological cancer after prostate cancer, bladder metastases are rare, and those originating from the stomach are exceptional. Secondary bladder metastases of signet ring cell carcinoma (SRCC) are an exceptional occurrence, presenting considerable diagnostic and therapeutic challenges. The aim is to present two rare cases of secondary bladder tumors arising from primary gastric tumors in order to better characterize their clinicopathological features and diagnosis. We report two cases of patients aged 58 and 21, respectively, presenting with macroscopic hematuria and acute obstructive renal failure, with abnormalities suspected during cystoscopy. Bladder biopsy, accompanied by histopathological analysis, revealed a poorly differentiated signet ring cell adenocarcinoma, linked to the previously identified gastric lesion. The patients were referred for chemotherapy, and one died six months after diagnosis. Bladder metastasis from gastric signet-ring cell carcinoma is extremely rare, but it should be considered when patients with gastric signet-ring cell carcinoma develop urinary symptoms.</p>
      </abstract>
      <kwd-group kwd-group-type="author-generated" xml:lang="en">
        <kwd>Bladder Metastasis</kwd>
        <kwd>Gastric Adenocarcinoma</kwd>
        <kwd>Signet Ring Cells</kwd>
        <kwd>SRCC</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec1">
      <title>1. Introduction</title>
      <p>Bladder cancer is the ninth most common cancer worldwide, with approximately 614,000 new cases and 220,000 deaths estimated in 2022 [<xref ref-type="bibr" rid="B1">1</xref>]. In France, the number of new cases of invasive bladder cancer was estimated at 13,074 in 2018, with 5335 deaths [<xref ref-type="bibr" rid="B2">2</xref>]. Bladder metastases are rare: in the largest published series of secondary bladder neoplasms, they represented 2.3% of all bladder neoplasms examined, and the stomach was the primary site in 4.3% of them [<xref ref-type="bibr" rid="B3">3</xref>]. Among these, gastric signet-ring cell carcinomas (SRCCs) represent an exceptional presentation, posing major diagnostic and therapeutic challenges. These tumors are characterized histologically by intracytoplasmic mucin displacing the nucleus to the periphery, giving them the characteristic “signet ring” appearance [<xref ref-type="bibr" rid="B4">4</xref>]. It is important to distinguish this form from signet ring cell primary bladder adenocarcinoma, which is itself extremely rare. Given the rarity of bladder metastasis from gastric SRCC, we report two cases to better characterize their anatomoclinical, radiological, and therapeutic features. </p>
    </sec>
    <sec id="sec2">
      <title>2. Case Presentations</title>
      <sec id="sec2dot1">
        <title>2.1. Case 1</title>
        <p>This is a 58-year-old hypertensive patient with a history of smoking (60 pack-years) and abstinence from alcohol. He was hospitalized in nephrology for malaise, difficulty swallowing, and abdominal pain, with a decline in his general condition that had been progressing for 3 months (WHO score 2). Urological examination revealed paroxysmal, non-clotting macroscopic hematuria. Digital rectal examination showed a small, firm prostate with an infiltrated bladder base. Laboratory tests revealed acute kidney injury (KDIGO 1) with a serum creatinine level of 100 µmol/L.</p>
        <p>Uro-CT scan revealed moderate bilateral ureterohydronephrosis proximal to bladder wall thickening (<xref ref-type="fig" rid="fig1">Figure 1</xref>). </p>
        <fig id="fig1">
          <label>Figure 1</label>
          <caption>
            <p>Bladder wall thickening.</p>
          </caption>
          <graphic xlink:href="https://html.scirp.org/file/5001181-rId17.jpeg?20261118013209" />
        </fig>
        <p>Gastroscopy revealed a suspicious ulcerated subcardial lesion. Multiple biopsies confirmed an invasive gastric adenocarcinoma with poorly differentiated signet ring cells. We noted an absence of HER2 expression and positive PD-L1 expression (20%).</p>
        <p>Cystoscopy had shown diffuse inflammatory lesions predominating at the level of the bladder dome without any detectable polyps and non-visualized ureteral orifices (<xref ref-type="fig" rid="fig2">Figure 2</xref>). There was no urinary drainage.</p>
        <fig id="fig2">
          <label>Figure 2</label>
          <caption>
            <p>Macroscopic appearance of an inflammatory bladder lesion.</p>
          </caption>
          <graphic xlink:href="https://html.scirp.org/file/5001181-rId18.jpeg?20261118013209" />
        </fig>
        <p>Bladder biopsy by transurethral resection of the bladder with image optimization technique (HEXVIX) and histopathological examination concluded that the bladder mucosa was invaded by signet ring cell adenocarcinoma, the mode of infiltration of which appeared to be secondary, related to the known gastric lesion, rather than primary (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Furthermore, the presence of intracellular mucus, the negative GATA3 test (<xref ref-type="fig" rid="fig4">Figure 4</xref>), and the absence of carcinoma <italic>in situ</italic> (CIS) were compatible with, but did not by themselves establish, a non-urothelial origin.</p>
        <fig id="fig3">
          <label>Figure 3</label>
          <caption>
            <p>The bladder mucosa is infiltrated by tumor cells with large, hyperchromatic nuclei pushed to the periphery by abundant cytoplasm, giving them a “signet ring” appearance.</p>
          </caption>
          <graphic xlink:href="https://html.scirp.org/file/5001181-rId19.jpeg?20261118013209" />
        </fig>
        <fig id="fig4">
          <label>Figure 4</label>
          <caption>
            <p>Immunohistological examination of GATA3, absence of nuclear staining.</p>
          </caption>
          <graphic xlink:href="https://html.scirp.org/file/5001181-rId20.jpeg?20261118013209" />
        </fig>
        <p>The PET scan revealed diffuse thickening of the gastric walls and the lower third of the esophagus, moderately hypermetabolic (SUVmax 4.3 in the gastric walls and SUVmax 5.7 at the esophagogastric junction). There was a small amount of fluid with low-metabolic abdominopelvic peritoneal thickening. No other suspicious hypermetabolic foci were identified. Given the peritoneal thickening with fluid, the infiltrated bladder base on rectal examination, and the absence of other hypermetabolic foci, peritoneal (transcoelomic) dissemination with secondary invasion of the bladder wall is the most plausible route of bladder involvement in this patient; hematogenous or lymphatic spread cannot be formally excluded.</p>
        <p>Following a multidisciplinary tumor board meeting, initial chemotherapy was decided upon. The patient was referred to oncology. The patient passed away after 11 months of chemotherapy. The protocol, however, is not known.</p>
      </sec>
      <sec id="sec2dot2">
        <title>2.2. Case 2</title>
        <p>A 21-year-old patient with no significant past medical history presented with bloody diarrhea, a decline in general condition (WHO 3), and acute obstructive renal failure with a serum creatinine level of 141 µmol/L.</p>
        <p>A thoraco-abdomino-pelvic CT scan revealed gastric wall thickening, a peritoneal carcinomatosis nodule, moderate ascites, bilateral dilation of the renal pelvis and calyces, and a cluster of bilateral lateral aortic lymphadenopathy (<xref ref-type="fig" rid="fig5">Figure 5</xref>). The peritoneal carcinomatosis nodule with ascites makes peritoneal (transcoelomic) dissemination the most likely route of bladder involvement; the lateral aortic lymphadenopathy indicates retroperitoneal nodal disease but does not by itself demonstrate a lymphatic route to the bladder, and hematogenous spread cannot be assessed from the available data.</p>
        <fig id="fig5">
          <label>Figure 5</label>
          <caption>
            <p>Gastric wall thickening.</p>
          </caption>
          <graphic xlink:href="https://html.scirp.org/file/5001181-rId21.jpeg?20261118013209" />
        </fig>
        <p>Gastroscopy revealed an edematous and difficult-to-pass pylorus. Biopsies confirmed a poorly differentiated signet-ring cell gastric carcinoma (<bold>Table 1</bold>).</p>
        <p><bold>Table 1</bold><bold>.</bold> Immunohistochemical results of the bladder and gastric specimens in both cases.</p>
        <table-wrap id="tbl1">
          <label>Table 1</label>
          <table>
            <tbody>
              <tr>
                <td>
                  <underline>
                    <bold>Marker</bold>
                  </underline>
                </td>
                <td>
                  <underline>
                    <bold>Case</bold>
                  </underline>
                  <underline>
                    <bold>1</bold>
                  </underline>
                  <underline>—</underline>
                  <underline>
                    <bold>bladder</bold>
                  </underline>
                </td>
                <td>
                  <underline>
                    <bold>Case</bold>
                  </underline>
                  <underline>
                    <bold>1</bold>
                  </underline>
                  <underline>—</underline>
                  <underline>
                    <bold>stomach</bold>
                  </underline>
                </td>
                <td>
                  <underline>
                    <bold>Case</bold>
                  </underline>
                  <underline>
                    <bold>2</bold>
                  </underline>
                  <underline>—</underline>
                  <underline>
                    <bold>bladder</bold>
                  </underline>
                </td>
                <td>
                  <underline>
                    <bold>Case</bold>
                  </underline>
                  <underline>
                    <bold>2</bold>
                  </underline>
                  <underline>—</underline>
                  <underline>
                    <bold>stomach</bold>
                  </underline>
                </td>
              </tr>
              <tr>
                <td>GATA3</td>
                <td>Negative</td>
                <td>Not done</td>
                <td>Negative</td>
                <td>Positive</td>
              </tr>
              <tr>
                <td>CK20</td>
                <td>Negative</td>
                <td>Not done</td>
                <td>Not done</td>
                <td>Not done</td>
              </tr>
              <tr>
                <td>CK7</td>
                <td>Positive</td>
                <td>Positive</td>
                <td>Positive</td>
                <td>Positive</td>
              </tr>
              <tr>
                <td>p63</td>
                <td>Negative</td>
                <td>Negative</td>
                <td>Negative</td>
                <td>Negative</td>
              </tr>
              <tr>
                <td>Uroplakin III</td>
                <td>Not done</td>
                <td>Not done</td>
                <td>Not done</td>
                <td>Not done</td>
              </tr>
              <tr>
                <td>AE1/AE2</td>
                <td>Positive</td>
                <td>Positive</td>
                <td>Positive</td>
                <td>Positive</td>
              </tr>
              <tr>
                <td>HER2</td>
                <td>Not done</td>
                <td>Negative (score 0)</td>
                <td>Not done</td>
                <td>Negative (score 0)</td>
              </tr>
              <tr>
                <td>PD-L1 (CPS)</td>
                <td>Not done</td>
                <td>Positive (20%)</td>
                <td>Not done</td>
                <td>Positive (30%)</td>
              </tr>
              <tr>
                <td>MMR/MSI</td>
                <td>Not done</td>
                <td>Negative</td>
                <td>Not done</td>
                <td>Negative</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Cystoscopy performed during upper urinary tract drainage (bilateral ureteral stents) showed inflammatory lesions in the trigone, and biopsies were taken during the same surgical procedure. The results were consistent with signet-ring cell adenocarcinoma secondary to the gastric lesion.</p>
        <p>Serum creatinine levels normalized postoperatively, and after multidisciplinary team meeting, the patient was referred to oncology for chemotherapy. The patient died six months after diagnosis from complications of the disease.</p>
      </sec>
    </sec>
    <sec id="sec3">
      <title>3. Discussion</title>
      <p>Bladder metastases from gastric tumors are rare [<xref ref-type="bibr" rid="B4">4</xref>]; secondary neoplasms account for 1.6% - 3.0% of solid malignancies in genitourinary surgical specimens [<xref ref-type="bibr" rid="B5">5</xref>]. In cases of bladder metastasis from a distant primary cancer, the stomach is among the most frequently reported primary sites, together with skin (melanoma), lung, and breast [<xref ref-type="bibr" rid="B5">5</xref>]. Several routes of spread to the bladder have been proposed for gastric adenocarcinoma: transcoelomic (peritoneal) seeding with implantation of tumor cells on pelvic structures, lymphatic dissemination [<xref ref-type="bibr" rid="B6">6</xref>], and hematogenous dissemination [<xref ref-type="bibr" rid="B7">7</xref>]. These mechanisms are not mutually exclusive and are rarely demonstrable in an individual patient. In our patients, the peritoneal findings (peritoneal thickening with fluid in case 1; a peritoneal carcinomatosis nodule with ascites in case 2) make peritoneal dissemination with secondary invasion of the bladder wall the most plausible route. The lateral aortic lymphadenopathy in case 2 does not by itself establish a lymphatic route, and a hematogenous route cannot be proven or excluded in either patient. Gastrointestinal origin should be suspected when a bladder biopsy shows signet-ring cell adenocarcinoma; the stomach, colon, and breast are the main primary sites to exclude [<xref ref-type="bibr" rid="B8">8</xref>].</p>
      <p>In the series by Ganem <italic>et al.</italic> (1994) [<xref ref-type="bibr" rid="B9">9</xref>], secondary bladder tumors represented 0.17% of cystectomy specimens, with a predominance of gastrointestinal origins. In a review of 18 reported cases of bladder metastasis from a primary gastric tumor, hematuria was the only consistent urinary symptom (12/18 patients), and the bladder metastasis could be synchronous or metachronous, with a mean interval of six years after the gastric primary [<xref ref-type="bibr" rid="B10">10</xref>]. The presentation is often misleading. The most frequent symptoms are macroscopic hematuria, bladder irritation, and sometimes obstructive symptoms. In some reported cases, bladder metastasis revealed the primary tumor. In our patients, hematuria and acute obstructive renal failure were the presenting urological signs. The lesion may be single or multiple and may mimic a primary urothelial tumor [<xref ref-type="bibr" rid="B10">10</xref>].</p>
      <p>The diagnosis is based on biopsy and histopathological analysis. The histological appearance shows sheets of signet ring cells with abundant intracytoplasmic mucin (PAS+, Alcian blue+) (<xref ref-type="fig" rid="fig6">Figure 6</xref>).</p>
      <fig id="fig6">
        <label>Figure 6</label>
        <caption>
          <p>Alcian blue positivity.</p>
        </caption>
        <graphic xlink:href="https://html.scirp.org/file/5001181-rId22.jpeg?20261118013209" />
      </fig>
      <p>Immunohistochemistry is essential for identifying the primary tumor. For tumors of gastric origin, positivity is observed for the markers CDX2, CK20, MUC5AC, and MUC6. For primary bladder tumors, the markers CK7, GATA3, and p63 are positive, and the marker CDX2 is negative [<xref ref-type="bibr" rid="B11">11</xref>]. No single marker is conclusive, since CK7 and CK20 may be variably expressed in both settings, and the assignment of origin rests on the panel as a whole in its clinical context. In our patients, the diagnosis of bladder metastasis from a gastric primary is based on the combination of the known gastric SRCC, the histology (signet-ring cells with intracytoplasmic mucin), and the immunohistochemical profile summarized in <bold>Table 1</bold>; negative GATA3 staining and the absence of CIS are supportive but not sufficient on their own.</p>
      <p>It is important to distinguish this form from signet ring cell primary bladder adenocarcinoma, which is itself exceptional (&lt;0.5% of bladder tumors), notably described by Grignon <italic>et al.</italic> in 1991 [<xref ref-type="bibr" rid="B12">12</xref>]. Several factors can help differentiate between the two: first, the clinical history, which generally guides the diagnosis, as was the case with our patients. The cystoscopic appearance can also be useful. Indeed, unlike primary bladder cancer, secondary tumors are usually solitary and most often located in the trigone or bladder neck; in our patients, the lesions predominated at the bladder dome (case 1, diffuse inflammatory lesions) and in the trigone (case 2). Histologically, however, signet ring cell bladder adenocarcinomas are indistinguishable from their counterparts in other organs.</p>
      <p>There is no established therapeutic consensus specific to bladder metastasis from gastric SRCC. Systemic treatment is determined by the metastatic gastric primary, whereas urinary obstruction and hematuria require separate local management. Systemic treatment. In unresectable or metastatic gastric adenocarcinoma, first-line treatment is a fluoropyrimidine-platinum doublet (FOLFOX or CAPOX), selected according to biomarkers [<xref ref-type="bibr" rid="B13">13</xref>] [<xref ref-type="bibr" rid="B14">14</xref>]. Trastuzumab is added in HER2-positive disease [<xref ref-type="bibr" rid="B15">15</xref>]; an anti-PD-1 antibody (nivolumab with chemotherapy) improved survival in untreated advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma, with the greatest benefit at higher PD-L1 CPS [<xref ref-type="bibr" rid="B16">16</xref>]; and zolbetuximab plus mFOLFOX6 improved outcomes in CLDN18.2-positive, HER2-negative disease [<xref ref-type="bibr" rid="B17">17</xref>]. HER2, PD-L1 CPS, MSI/MMR, and CLDN18.2 status should therefore be documented at diagnosis [<xref ref-type="bibr" rid="B18">18</xref>]. These data come from trials in gastric and gastroesophageal junction adenocarcinoma and not from patients with bladder metastasis; the prognostic impact of signet-ring histology and its sensitivity to chemotherapy remain debated [<xref ref-type="bibr" rid="B19">19</xref>]. Local management. Obstructive uropathy from bladder involvement is treated independently of systemic therapy by urinary decompression, using retrograde ureteral stenting or percutaneous nephrostomy depending on feasibility (the ureteral orifices may not be identifiable when the bladder base is infiltrated), expected survival, and quality of life [<xref ref-type="bibr" rid="B20">20</xref>]. Transurethral resection serves to establish the diagnosis and may help control hematuria. (To complete: local procedures actually performed in each patient.) The prognosis is poor: in a recent single-centre series of secondary bladder neoplasms, the two patients with a gastric primary had a median survival of 66 days [<xref ref-type="bibr" rid="B21">21</xref>], and malignant ureteral obstruction from advanced malignancy carries a median survival of 3 to 7 months [<xref ref-type="bibr" rid="B22">22</xref>]. After multidisciplinary discussion, the patients were referred to oncology for chemotherapy and died 11 and 6 months after diagnosis.</p>
    </sec>
    <sec id="sec4">
      <title>4. Conclusion</title>
      <p>Bladder metastases from signet ring cell adenocarcinomas are a rare and difficult-to-diagnose entity, requiring rigorous correlation of clinical, endoscopic, radiological, and histopathological data. Immunohistochemistry is the key tool for determining the primary origin and guiding treatment. The prognosis remains poor, and management must be part of a multidisciplinary oncological approach centered on the primary tumor, with decompression of the urinary tract when needed.</p>
    </sec>
    <sec id="sec5">
      <title>Ethics and Publication Statements</title>
      <p>Both patients died before the preparation of this manuscript. Despite several attempts to reach their next of kin by telephone, no contact could be established, and consent for publication could therefore not be obtained. All information that could identify the patients has been removed from the text, and none of the images (CT, cystoscopy, histology) contains any element allowing their identification.</p>
    </sec>
    <sec id="sec6">
      <title>Author Contributions</title>
      <p>Djiby Dieng, Mohamed Ben Jemaa, and Emmanuel Van Glabeke participated in patient care and the writing of this article. Abdelghani Benaida also participated in patient care. All authors contributed to this work and declare that they have read and approved the final version of the manuscript. </p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., <italic>et al</italic>. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. <italic>CA</italic>: <italic>A Cancer Journal for Clinicians</italic>, 74, 229-263. https://doi.org/10.3322/caac.21834 <pub-id pub-id-type="doi">10.3322/caac.21834</pub-id><pub-id pub-id-type="pmid">38572751</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3322/caac.21834">https://doi.org/10.3322/caac.21834</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Bray, F.</string-name>
              <string-name>Laversanne, M.</string-name>
              <string-name>Sung, H.</string-name>
              <string-name>Ferlay, J.</string-name>
              <string-name>Siegel, R.L.</string-name>
              <string-name>Soerjomataram, I.</string-name>
            </person-group>
            <year>2024</year>
            <article-title>Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</article-title>
            <source>CA: A Cancer Journal for Clinicians</source>
            <volume>74</volume>
            <pub-id pub-id-type="doi">10.3322/caac.21834</pub-id>
            <pub-id pub-id-type="pmid">38572751</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B2">
        <label>2.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Daubisse-Marliac, L., Grosclaude, P., Plouvier, S., <italic>et al</italic>. (25021) Survie des personnes atteintes de cancer en France métropolitaine 1989-2018—Vessie. Santé publique France.</mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Daubisse-Marliac, L.</string-name>
              <string-name>Grosclaude, P.</string-name>
              <string-name>Plouvier, S.</string-name>
            </person-group>
            <year>1989</year>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B3">
        <label>3.</label>
        <citation-alternatives>
          <mixed-citation publication-type="report">András, C., Tóth, L., Pósán, J., Csiki, E., Tanyi, M., Csiki, Z., <italic>et al</italic>. (2013) Occurrence of Bladder Metastasis 10 Years after Surgical Removal of a Primary Gastric Cancer: A Case Report and Review of the Literature. <italic>Journal of Medical Case Reports</italic>, 7, Article No. 204. https://doi.org/10.1186/1752-1947-7-204 <pub-id pub-id-type="doi">10.1186/1752-1947-7-204</pub-id><pub-id pub-id-type="pmid">23945465</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1752-1947-7-204">https://doi.org/10.1186/1752-1947-7-204</ext-link></mixed-citation>
          <element-citation publication-type="report">
            <person-group person-group-type="author">
              <string-name>Csiki, E.</string-name>
              <string-name>Tanyi, M.</string-name>
              <string-name>Csiki, Z.</string-name>
            </person-group>
            <year>2013</year>
            <article-title>Occurrence of Bladder Metastasis 10 Years after Surgical Removal of a Primary Gastric Cancer: A Case Report and Review of the Literature</article-title>
            <source>Journal of Medical Case Reports</source>
            <volume>7</volume>
            <elocation-id>No</elocation-id>
            <pub-id pub-id-type="doi">10.1186/1752-1947-7-204</pub-id>
            <pub-id pub-id-type="pmid">23945465</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B4">
        <label>4.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Sharma, P.K., Vijay, M.K., Das, R.K. and Chatterjee, U. (2011) Secondary Signet-Ring Cell Adenocarcinoma of Urinary Bladder from a Gastric Primary. <italic>Urology Annals</italic>, 3, 97-99. https://doi.org/10.4103/0974-7796.82177 <pub-id pub-id-type="doi">10.4103/0974-7796.82177</pub-id><pub-id pub-id-type="pmid">21747602</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4103/0974-7796.82177">https://doi.org/10.4103/0974-7796.82177</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Sharma, P.K.</string-name>
              <string-name>Vijay, M.K.</string-name>
              <string-name>Das, R.K.</string-name>
              <string-name>Chatterjee, U.</string-name>
            </person-group>
            <year>2011</year>
            <article-title>Secondary Signet-Ring Cell Adenocarcinoma of Urinary Bladder from a Gastric Primary</article-title>
            <source>Urology Annals</source>
            <volume>3</volume>
            <pub-id pub-id-type="doi">10.4103/0974-7796.82177</pub-id>
            <pub-id pub-id-type="pmid">21747602</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B5">
        <label>5.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Bates, A.W. and Baithun, S.I. (2000) Secondary Neoplasms of the Bladder Are Histological Mimics of Nontransitional Cell Primary Tumours: Clinicopathological and Histological Features of 282 Cases. <italic>Histopathology</italic>, 36, 32-40. https://doi.org/10.1046/j.1365-2559.2000.00797.x <pub-id pub-id-type="doi">10.1046/j.1365-2559.2000.00797.x</pub-id><pub-id pub-id-type="pmid">10632749</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1046/j.1365-2559.2000.00797.x">https://doi.org/10.1046/j.1365-2559.2000.00797.x</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Bates, A.W.</string-name>
              <string-name>Baithun, S.I.</string-name>
            </person-group>
            <year>2000</year>
            <article-title>Secondary Neoplasms of the Bladder Are Histological Mimics of Nontransitional Cell Primary Tumours: Clinicopathological and Histological Features of 282 Cases</article-title>
            <source>Histopathology</source>
            <volume>36</volume>
            <pub-id pub-id-type="doi">10.1046/j.1365-2559.2000.00797.x</pub-id>
            <pub-id pub-id-type="pmid">10632749</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B6">
        <label>6.</label>
        <citation-alternatives>
          <mixed-citation publication-type="report">Uemura, M., Inoue, H., Nishimura, K., Mizutani, S. and Miyoshi, S. (2000) Metastatic Bladder Tumor Disseminated Lymphogenously from Gastric Cancer: A Case Report. <italic>Hinyokika Kiyo</italic>, 46, 723-725.</mixed-citation>
          <element-citation publication-type="report">
            <person-group person-group-type="author">
              <string-name>Uemura, M.</string-name>
              <string-name>Inoue, H.</string-name>
              <string-name>Nishimura, K.</string-name>
              <string-name>Mizutani, S.</string-name>
              <string-name>Miyoshi, S.</string-name>
            </person-group>
            <year>2000</year>
            <article-title>Metastatic Bladder Tumor Disseminated Lymphogenously from Gastric Cancer: A Case Report</article-title>
            <source>Hinyokika Kiyo</source>
            <volume>46</volume>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B7">
        <label>7.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Antunes, A.A., Siqueira Jr, T.M. and Falcão, E. (2004) Vesical Metastasis of Gastric Adenocarcinoma. <italic>International Brazilian Journal of Urology</italic>, 30, 403-405. https://doi.org/10.1590/s1677-55382004000500009 <pub-id pub-id-type="doi">10.1590/s1677-55382004000500009</pub-id><pub-id pub-id-type="pmid">15610575</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/s1677-55382004000500009">https://doi.org/10.1590/s1677-55382004000500009</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Antunes, A.A.</string-name>
              <string-name>Jr, T.M.</string-name>
            </person-group>
            <year>2004</year>
            <article-title>Vesical Metastasis of Gastric Adenocarcinoma</article-title>
            <source>International Brazilian Journal of Urology</source>
            <volume>30</volume>
            <pub-id pub-id-type="doi">10.1590/s1677-55382004000500009</pub-id>
            <pub-id pub-id-type="pmid">15610575</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B8">
        <label>8.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Vigliar, E., Marino, G., Matano, E., Imbimbo, C., Rossella, D.C. and Insabato, L. (2012) Signet-Ring-Cell Carcinoma of Stomach Metastatic to the Bladder. <italic>International Journal of Surgical Pathology</italic>, 21, 72-75. https://doi.org/10.1177/1066896912445922 <pub-id pub-id-type="doi">10.1177/1066896912445922</pub-id><pub-id pub-id-type="pmid">22692905</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1177/1066896912445922">https://doi.org/10.1177/1066896912445922</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Vigliar, E.</string-name>
              <string-name>Marino, G.</string-name>
              <string-name>Matano, E.</string-name>
              <string-name>Imbimbo, C.</string-name>
              <string-name>Rossella, D.C.</string-name>
              <string-name>Insabato, L.</string-name>
            </person-group>
            <year>2012</year>
            <article-title>Signet-Ring-Cell Carcinoma of Stomach Metastatic to the Bladder</article-title>
            <source>International Journal of Surgical Pathology</source>
            <volume>21</volume>
            <pub-id pub-id-type="doi">10.1177/1066896912445922</pub-id>
            <pub-id pub-id-type="pmid">22692905</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B9">
        <label>9.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Ganem, E.J., Bhatt, G.M. and Miles, B.J. (1994) Secondary Tumors of the Urinary Bladder. <italic>Urology</italic>, 42, 457-461.</mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Ganem, E.J.</string-name>
              <string-name>Bhatt, G.M.</string-name>
              <string-name>Miles, B.J.</string-name>
            </person-group>
            <year>1994</year>
            <article-title>Secondary Tumors of the Urinary Bladder</article-title>
            <source>Urology</source>
            <volume>42</volume>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B10">
        <label>10.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Nouioui, M.A., Saadi, A., Chakroun, M., Oueslati, A., Ksentini, M., Bouzouita, A., <italic>et</italic><italic>al</italic>. (2020) Unusual Bladder Metastasis from a Primary Gastric Carcinoma: Two Case Reports and Review of Literature. <italic>Case Reports in Urology</italic>, 2020, Article ID: 8848841. https://doi.org/10.1155/2020/8848841 <pub-id pub-id-type="doi">10.1155/2020/8848841</pub-id><pub-id pub-id-type="pmid">33274106</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1155/2020/8848841">https://doi.org/10.1155/2020/8848841</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Nouioui, M.A.</string-name>
              <string-name>Saadi, A.</string-name>
              <string-name>Chakroun, M.</string-name>
              <string-name>Oueslati, A.</string-name>
              <string-name>Ksentini, M.</string-name>
              <string-name>Bouzouita, A.</string-name>
            </person-group>
            <year>2020</year>
            <article-title>Unusual Bladder Metastasis from a Primary Gastric Carcinoma: Two Case Reports and Review of Literature</article-title>
            <source>Case Reports in Urology</source>
            <volume>2020</volume>
            <fpage>884884</fpage>
            <elocation-id>ID</elocation-id>
            <pub-id pub-id-type="doi">10.1155/2020/8848841</pub-id>
            <pub-id pub-id-type="pmid">33274106</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B11">
        <label>11.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Wang, H.L., Lu, D.W., Yerian, L.M., Alsikafi, N., Steinberg, G., Hart, J., <italic>et al</italic>. (2001) Immunohistochemical Distinction between Primary Adenocarcinoma of the Bladder and Secondary Colorectal Adenocarcinoma. <italic>The American Journal of Surgical Pathology</italic>, 25, 1380-1387. https://doi.org/10.1097/00000478-200111000-00005 <pub-id pub-id-type="doi">10.1097/00000478-200111000-00005</pub-id><pub-id pub-id-type="pmid">11684954</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/00000478-200111000-00005">https://doi.org/10.1097/00000478-200111000-00005</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Wang, H.L.</string-name>
              <string-name>Lu, D.W.</string-name>
              <string-name>Yerian, L.M.</string-name>
              <string-name>Alsikafi, N.</string-name>
              <string-name>Steinberg, G.</string-name>
              <string-name>Hart, J.</string-name>
            </person-group>
            <year>2001</year>
            <article-title>Immunohistochemical Distinction between Primary Adenocarcinoma of the Bladder and Secondary Colorectal Adenocarcinoma</article-title>
            <source>The American Journal of Surgical Pathology</source>
            <volume>25</volume>
            <pub-id pub-id-type="doi">10.1097/00000478-200111000-00005</pub-id>
            <pub-id pub-id-type="pmid">11684954</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B12">
        <label>12.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Grignon, D.J., Ro, J.Y., Ayala, A.G., Johnson, D.E. and Ordóñez, N.G. (1991) Primary Adenocarcinoma of the Urinary Bladder. a Clinicopathologic Analysis of 72 Cases. <italic>Cancer</italic>, 67, 2165-2172. https://doi.org/10.1002/1097-0142(19910415)67:8&lt;2165::aid-cncr2820670827&gt;3.0.co;2-m <pub-id pub-id-type="doi">10.1002/1097-0142(19910415)67:8&lt;2165::aid-cncr2820670827&gt;3.0.co;2-m</pub-id><pub-id pub-id-type="pmid">1706216</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/1097-0142(19910415)67:8%3C2165::aid-cncr2820670827%3E3.0.co;2-m">https://doi.org/10.1002/1097-0142(19910415)67:8&lt;2165::aid-cncr2820670827&gt;3.0.co;2-m</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Grignon, D.J.</string-name>
              <string-name>Ro, J.Y.</string-name>
              <string-name>Ayala, A.G.</string-name>
              <string-name>Johnson, D.E.</string-name>
            </person-group>
            <year>1991</year>
            <article-title>Primary Adenocarcinoma of the Urinary Bladder</article-title>
            <source>a Clinicopathologic Analysis of 72 Cases. Cancer</source>
            <volume>67</volume>
            <fpage>8</fpage>
            <pub-id pub-id-type="doi">10.1002/1097-0142(19910415)67:8&lt;2165::aid-cncr2820670827&gt;3.0.co;2-m</pub-id>
            <pub-id pub-id-type="pmid">1706216</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B13">
        <label>13.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Smyth, E.C., Nilsson, M., Grabsch, H.I., van Grieken, N.C. and Lordick, F. (2020) Gastric Cancer. <italic>The Lancet</italic>, 396, 635-648. https://doi.org/10.1016/s0140-6736(20)31288-5 <pub-id pub-id-type="doi">10.1016/s0140-6736(20)31288-5</pub-id><pub-id pub-id-type="pmid">32861308</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/s0140-6736(20)31288-5">https://doi.org/10.1016/s0140-6736(20)31288-5</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Smyth, E.C.</string-name>
              <string-name>Nilsson, M.</string-name>
              <string-name>Grabsch, H.I.</string-name>
              <string-name>Grieken, N.C.</string-name>
              <string-name>Lordick, F.</string-name>
            </person-group>
            <year>2020</year>
            <article-title>Gastric Cancer</article-title>
            <source>The Lancet</source>
            <volume>6736</volume>
            <issue>20</issue>
            <pub-id pub-id-type="doi">10.1016/s0140-6736(20)31288-5</pub-id>
            <pub-id pub-id-type="pmid">32861308</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B14">
        <label>14.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Joshi, S.S. and Badgwell, B.D. (2021) Current Treatment and Recent Progress in Gastric Cancer. <italic>CA</italic>: <italic>A Cancer Journal for Clinicians</italic>, 71, 264-279. https://doi.org/10.3322/caac.21657 <pub-id pub-id-type="doi">10.3322/caac.21657</pub-id><pub-id pub-id-type="pmid">33592120</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3322/caac.21657">https://doi.org/10.3322/caac.21657</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Joshi, S.S.</string-name>
              <string-name>Badgwell, B.D.</string-name>
            </person-group>
            <year>2021</year>
            <article-title>Current Treatment and Recent Progress in Gastric Cancer</article-title>
            <source>CA: A Cancer Journal for Clinicians</source>
            <volume>71</volume>
            <pub-id pub-id-type="doi">10.3322/caac.21657</pub-id>
            <pub-id pub-id-type="pmid">33592120</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B15">
        <label>15.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Bang, Y., Van Cutsem, E., Feyereislova, A., Chung, H.C., Shen, L., Sawaki, A., <italic>et al</italic>. (2010) Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial. <italic>The Lancet</italic>, 376, 687-697. https://doi.org/10.1016/s0140-6736(10)61121-x <pub-id pub-id-type="doi">10.1016/s0140-6736(10)61121-x</pub-id><pub-id pub-id-type="pmid">20728210</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/s0140-6736(10)61121-x">https://doi.org/10.1016/s0140-6736(10)61121-x</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Bang, Y.</string-name>
              <string-name>Cutsem, E.</string-name>
              <string-name>Feyereislova, A.</string-name>
              <string-name>Chung, H.C.</string-name>
              <string-name>Shen, L.</string-name>
              <string-name>Sawaki, A.</string-name>
              <string-name>Open-Label, R</string-name>
            </person-group>
            <year>2010</year>
            <article-title>Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial</article-title>
            <source>The Lancet</source>
            <volume>6736</volume>
            <issue>10</issue>
            <pub-id pub-id-type="doi">10.1016/s0140-6736(10)61121-x</pub-id>
            <pub-id pub-id-type="pmid">20728210</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B16">
        <label>16.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Janjigian, Y.Y., Shitara, K., Moehler, M., Garrido, M., Salman, P., Shen, L., <italic>et al</italic>. (2021) First-line Nivolumab Plus Chemotherapy versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial. <italic>The Lancet</italic>, 398, 27-40. https://doi.org/10.1016/s0140-6736(21)00797-2 <pub-id pub-id-type="doi">10.1016/s0140-6736(21)00797-2</pub-id><pub-id pub-id-type="pmid">34102137</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/s0140-6736(21)00797-2">https://doi.org/10.1016/s0140-6736(21)00797-2</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Janjigian, Y.Y.</string-name>
              <string-name>Shitara, K.</string-name>
              <string-name>Moehler, M.</string-name>
              <string-name>Garrido, M.</string-name>
              <string-name>Salman, P.</string-name>
              <string-name>Shen, L.</string-name>
              <string-name>Gastric, G</string-name>
              <string-name>Randomised, O</string-name>
              <string-name>Label, P</string-name>
            </person-group>
            <year>2021</year>
            <article-title>First-line Nivolumab Plus Chemotherapy versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial</article-title>
            <source>The Lancet</source>
            <volume>6736</volume>
            <issue>21</issue>
            <pub-id pub-id-type="doi">10.1016/s0140-6736(21)00797-2</pub-id>
            <pub-id pub-id-type="pmid">34102137</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B17">
        <label>17.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Shitara, K., Lordick, F., Bang, Y., Enzinger, P., Ilson, D., Shah, M.A., <italic>et al</italic>. (2023) Zolbetuximab Plus Mfolfox6 in Patients with CLDN18.2-Positive, HER2-Negative, Untreated, Locally Advanced Unresectable or Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma (SPOTLIGHT): A Multicentre, Randomised, Double-Blind, Phase 3 Trial. <italic>The Lancet</italic>, 401, 1655-1668. https://doi.org/10.1016/s0140-6736(23)00620-7 <pub-id pub-id-type="doi">10.1016/s0140-6736(23)00620-7</pub-id><pub-id pub-id-type="pmid">37068504</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/s0140-6736(23)00620-7">https://doi.org/10.1016/s0140-6736(23)00620-7</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Shitara, K.</string-name>
              <string-name>Lordick, F.</string-name>
              <string-name>Bang, Y.</string-name>
              <string-name>Enzinger, P.</string-name>
              <string-name>Ilson, D.</string-name>
              <string-name>Shah, M.A.</string-name>
              <string-name>Positive, H</string-name>
              <string-name>Negative, U</string-name>
              <string-name>Multicentre, R</string-name>
              <string-name>Double-Blind, P</string-name>
            </person-group>
            <year>2023</year>
            <article-title>Zolbetuximab Plus Mfolfox6 in Patients with CLDN18</article-title>
            <source>2-Positive</source>
            <volume>6736</volume>
            <issue>23</issue>
            <pub-id pub-id-type="doi">10.1016/s0140-6736(23)00620-7</pub-id>
            <pub-id pub-id-type="pmid">37068504</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B18">
        <label>18.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Lordick, F., Carneiro, F., Cascinu, S., Fleitas, T., Haustermans, K., Piessen, G., <italic>et al</italic>. (2022) Gastric Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up. <italic>Annals of Oncology</italic>, 33, 1005-1020. https://doi.org/10.1016/j.annonc.2022.07.004 <pub-id pub-id-type="doi">10.1016/j.annonc.2022.07.004</pub-id><pub-id pub-id-type="pmid">35914639</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.annonc.2022.07.004">https://doi.org/10.1016/j.annonc.2022.07.004</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Lordick, F.</string-name>
              <string-name>Carneiro, F.</string-name>
              <string-name>Cascinu, S.</string-name>
              <string-name>Fleitas, T.</string-name>
              <string-name>Haustermans, K.</string-name>
              <string-name>Piessen, G.</string-name>
              <string-name>Diagnosis, T</string-name>
            </person-group>
            <year>2022</year>
            <article-title>Gastric Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up</article-title>
            <source>Annals of Oncology</source>
            <volume>33</volume>
            <pub-id pub-id-type="doi">10.1016/j.annonc.2022.07.004</pub-id>
            <pub-id pub-id-type="pmid">35914639</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B19">
        <label>19.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Pernot, S., Voron, T., Perkins, G., Lagorce-Pages, C., Berger, A. and Taieb, J. (2015) Signet-Ring Cell Carcinoma of the Stomach: Impact on Prognosis and Specific Therapeutic Challenge. <italic>World Journal of Gastroenterology</italic>, 21, 11428-11438. https://doi.org/10.3748/wjg.v21.i40.11428 <pub-id pub-id-type="doi">10.3748/wjg.v21.i40.11428</pub-id><pub-id pub-id-type="pmid">26523107</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3748/wjg.v21.i40.11428">https://doi.org/10.3748/wjg.v21.i40.11428</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Pernot, S.</string-name>
              <string-name>Voron, T.</string-name>
              <string-name>Perkins, G.</string-name>
              <string-name>Lagorce-Pages, C.</string-name>
              <string-name>Berger, A.</string-name>
              <string-name>Taieb, J.</string-name>
            </person-group>
            <year>2015</year>
            <article-title>Signet-Ring Cell Carcinoma of the Stomach: Impact on Prognosis and Specific Therapeutic Challenge</article-title>
            <source>World Journal of Gastroenterology</source>
            <volume>21</volume>
            <pub-id pub-id-type="doi">10.3748/wjg.v21.i40.11428</pub-id>
            <pub-id pub-id-type="pmid">26523107</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B20">
        <label>20.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Ganatra, A.M. and Loughlin, K.R. (2005) The Management of Malignant Ureteral Obstruction Treated with Ureteral Stents. <italic>Journal of Urology</italic>, 174, 2125-2128. https://doi.org/10.1097/01.ju.0000181807.56114.b7 <pub-id pub-id-type="doi">10.1097/01.ju.0000181807.56114.b7</pub-id><pub-id pub-id-type="pmid">16280741</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/01.ju.0000181807.56114.b7">https://doi.org/10.1097/01.ju.0000181807.56114.b7</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Ganatra, A.M.</string-name>
              <string-name>Loughlin, K.R.</string-name>
            </person-group>
            <year>2005</year>
            <article-title>The Management of Malignant Ureteral Obstruction Treated with Ureteral Stents</article-title>
            <source>Journal of Urology</source>
            <volume>174</volume>
            <pub-id pub-id-type="doi">10.1097/01.ju.0000181807.56114.b7</pub-id>
            <pub-id pub-id-type="pmid">16280741</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B21">
        <label>21.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">El-Taji, O., Al-Mitwalli, A., Malik, F., Agarwal, S., Gogbashian, A., Hughes, R., <italic>et al</italic>. (2021) Secondary Neoplasms of the Urinary Bladder-Clinical Management and Oncological Outcomes. <italic>Translational Andrology and Urology</italic>, 10, 2427-2434. https://doi.org/10.21037/tau-20-955 <pub-id pub-id-type="doi">10.21037/tau-20-955</pub-id><pub-id pub-id-type="pmid">34295729</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.21037/tau-20-955">https://doi.org/10.21037/tau-20-955</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>El-Taji, O.</string-name>
              <string-name>Al-Mitwalli, A.</string-name>
              <string-name>Malik, F.</string-name>
              <string-name>Agarwal, S.</string-name>
              <string-name>Gogbashian, A.</string-name>
              <string-name>Hughes, R.</string-name>
            </person-group>
            <year>2021</year>
            <article-title>Secondary Neoplasms of the Urinary Bladder-Clinical Management and Oncological Outcomes</article-title>
            <source>Translational Andrology and Urology</source>
            <volume>10</volume>
            <pub-id pub-id-type="doi">10.21037/tau-20-955</pub-id>
            <pub-id pub-id-type="pmid">34295729</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B22">
        <label>22.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Kouba, E., Wallen, E.M. and Pruthi, R.S. (2008) Management of Ureteral Obstruction Due to Advanced Malignancy: Optimizing Therapeutic and Palliative Outcomes. <italic>Journal of Urology</italic>, 180, 444-450. https://doi.org/10.1016/j.juro.2008.04.008 <pub-id pub-id-type="doi">10.1016/j.juro.2008.04.008</pub-id><pub-id pub-id-type="pmid">18550089</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.juro.2008.04.008">https://doi.org/10.1016/j.juro.2008.04.008</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Kouba, E.</string-name>
              <string-name>Wallen, E.M.</string-name>
              <string-name>Pruthi, R.S.</string-name>
            </person-group>
            <year>2008</year>
            <article-title>Management of Ureteral Obstruction Due to Advanced Malignancy: Optimizing Therapeutic and Palliative Outcomes</article-title>
            <source>Journal of Urology</source>
            <volume>180</volume>
            <pub-id pub-id-type="doi">10.1016/j.juro.2008.04.008</pub-id>
            <pub-id pub-id-type="pmid">18550089</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
    </ref-list>
  </back>
</article>